 Vera Fridman
Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Charcot-Marie-Tooth Disease | 9 | 2026 | 22 | 4.030 |
Why?
| | Diabetic Neuropathies | 6 | 2026 | 100 | 2.660 |
Why?
| | Hereditary Sensory and Autonomic Neuropathies | 2 | 2019 | 2 | 1.030 |
Why?
| | Leukodystrophy, Globoid Cell | 1 | 2022 | 8 | 0.750 |
Why?
| | Serine | 3 | 2022 | 143 | 0.740 |
Why?
| | Polyneuropathies | 1 | 2022 | 57 | 0.720 |
Why?
| | Neural Conduction | 3 | 2019 | 92 | 0.680 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2026 | 2588 | 0.660 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 142 | 0.640 |
Why?
| | Biomarkers | 4 | 2026 | 4295 | 0.630 |
Why?
| | Models, Theoretical | 1 | 2020 | 558 | 0.480 |
Why?
| | Mutation | 5 | 2023 | 4075 | 0.460 |
Why?
| | Spastic Paraplegia, Hereditary | 1 | 2014 | 12 | 0.420 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2015 | 134 | 0.420 |
Why?
| | Mononeuropathies | 1 | 2012 | 3 | 0.370 |
Why?
| | Clinical Trials as Topic | 2 | 2026 | 1061 | 0.320 |
Why?
| | Skin | 1 | 2015 | 753 | 0.310 |
Why?
| | Electromyography | 1 | 2012 | 419 | 0.300 |
Why?
| | Hepatic Encephalopathy | 1 | 2009 | 25 | 0.300 |
Why?
| | Brain Edema | 1 | 2009 | 62 | 0.290 |
Why?
| | Liver Failure, Acute | 1 | 2009 | 68 | 0.280 |
Why?
| | Obesity | 2 | 2021 | 3116 | 0.270 |
Why?
| | Genetic Predisposition to Disease | 1 | 2015 | 2378 | 0.250 |
Why?
| | Humans | 19 | 2026 | 145474 | 0.220 |
Why?
| | Sphingolipids | 3 | 2022 | 83 | 0.220 |
Why?
| | Treatment Outcome | 2 | 2019 | 11772 | 0.210 |
Why?
| | Intermediate Filaments | 1 | 2023 | 25 | 0.200 |
Why?
| | Longitudinal Studies | 2 | 2022 | 2953 | 0.200 |
Why?
| | Disease Progression | 2 | 2022 | 2864 | 0.200 |
Why?
| | Adolescent | 6 | 2024 | 22529 | 0.190 |
Why?
| | Galactosylceramidase | 1 | 2022 | 2 | 0.190 |
Why?
| | Myelin P0 Protein | 1 | 2022 | 7 | 0.190 |
Why?
| | Neurofilament Proteins | 1 | 2023 | 79 | 0.190 |
Why?
| | Adult | 7 | 2024 | 40777 | 0.180 |
Why?
| | Research Design | 1 | 2026 | 1137 | 0.160 |
Why?
| | Genetic Therapy | 1 | 2021 | 316 | 0.150 |
Why?
| | Serine C-Palmitoyltransferase | 1 | 2019 | 8 | 0.150 |
Why?
| | Male | 9 | 2024 | 72842 | 0.140 |
Why?
| | Hyperglycemia | 1 | 2022 | 379 | 0.140 |
Why?
| | Young Adult | 4 | 2024 | 14218 | 0.140 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2019 | 68 | 0.140 |
Why?
| | Middle Aged | 5 | 2024 | 36215 | 0.130 |
Why?
| | Brain | 2 | 2011 | 2947 | 0.130 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 572 | 0.130 |
Why?
| | Prediabetic State | 1 | 2020 | 249 | 0.130 |
Why?
| | Pain Measurement | 1 | 2019 | 561 | 0.120 |
Why?
| | Aged | 5 | 2024 | 26153 | 0.120 |
Why?
| | Severity of Illness Index | 2 | 2024 | 2930 | 0.120 |
Why?
| | Case-Control Studies | 1 | 2023 | 3623 | 0.110 |
Why?
| | Proteins | 1 | 2021 | 1023 | 0.110 |
Why?
| | Child, Preschool | 3 | 2024 | 11853 | 0.110 |
Why?
| | Sensitivity and Specificity | 1 | 2020 | 1997 | 0.110 |
Why?
| | Female | 8 | 2024 | 78844 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1097 | 0.100 |
Why?
| | Double-Blind Method | 1 | 2019 | 2062 | 0.100 |
Why?
| | Quality of Life | 1 | 2026 | 3204 | 0.100 |
Why?
| | Data Collection | 1 | 2015 | 640 | 0.090 |
Why?
| | Risk Factors | 1 | 2026 | 10885 | 0.090 |
Why?
| | Lymphopenia | 1 | 2011 | 62 | 0.080 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2011 | 38 | 0.080 |
Why?
| | Analgesics, Opioid | 1 | 2020 | 1149 | 0.080 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2009 | 47 | 0.070 |
Why?
| | Coma | 1 | 2009 | 38 | 0.070 |
Why?
| | Nerve Degeneration | 1 | 2009 | 49 | 0.070 |
Why?
| | Diphenhydramine | 1 | 2009 | 36 | 0.070 |
Why?
| | Tachycardia | 1 | 2009 | 57 | 0.070 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5423 | 0.070 |
Why?
| | Time Factors | 1 | 2020 | 7123 | 0.070 |
Why?
| | Lower Extremity | 1 | 2012 | 445 | 0.070 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2009 | 128 | 0.070 |
Why?
| | Aged, 80 and over | 1 | 2020 | 8333 | 0.060 |
Why?
| | Hypnotics and Sedatives | 1 | 2009 | 222 | 0.060 |
Why?
| | Acetaminophen | 1 | 2009 | 267 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 6066 | 0.060 |
Why?
| | Multiple Sclerosis | 1 | 2011 | 489 | 0.060 |
Why?
| | Phenotype | 2 | 2024 | 3155 | 0.060 |
Why?
| | Suicide, Attempted | 1 | 2009 | 423 | 0.060 |
Why?
| | Recovery of Function | 1 | 2009 | 716 | 0.050 |
Why?
| | Animals | 3 | 2022 | 38030 | 0.050 |
Why?
| | Genes, Modifier | 1 | 2024 | 2 | 0.050 |
Why?
| | Myelin Proteins | 1 | 2024 | 45 | 0.050 |
Why?
| | Child | 2 | 2024 | 22707 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 2121 | 0.050 |
Why?
| | Connexins | 1 | 2023 | 54 | 0.050 |
Why?
| | Mutation, Missense | 1 | 2023 | 335 | 0.040 |
Why?
| | Hypertension | 1 | 2009 | 1273 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2011 | 3904 | 0.040 |
Why?
| | Patient Selection | 1 | 2024 | 738 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2009 | 2769 | 0.040 |
Why?
| | Dietary Supplements | 1 | 2022 | 583 | 0.030 |
Why?
| | Dyslipidemias | 1 | 2020 | 184 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2015 | 17291 | 0.030 |
Why?
| | Mefloquine | 1 | 2011 | 1 | 0.020 |
Why?
| | Mianserin | 1 | 2011 | 3 | 0.020 |
Why?
| | JC Virus | 1 | 2011 | 23 | 0.020 |
Why?
| | Reference Values | 1 | 2011 | 798 | 0.020 |
Why?
| | Neuroimaging | 1 | 2011 | 297 | 0.020 |
Why?
| | Mice | 1 | 2022 | 18329 | 0.010 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2011 | 919 | 0.010 |
Why?
|
|
Fridman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|